Ireland's Alkermes Q3 revenue beats on LUMRYZ growth

Overview

• Ireland biopharma firm's Q3 revenue beat analyst expectations

• Q3 adjusted EPS was $0.09

Outlook

• Company did not provide specific guidance in the press release

Result Drivers

• LUMRYZ SALES – LUMRYZ generated $89.9 mln in quarterly revenue, with about 4,100 patients on therapy at quarter-end

• FAVORABLE PATIENT MIX – VIVITROL and ARISTADA recorded about $11 mln in gross-to-net favorability, primarily from favorable patient mix

• HIGHER EXPENSES AND INTEREST – GAAP net income fell to $16.3 mln as operating expenses rose and interest expense reached $27.6 mln

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Alkermes Plc is $57.00, about 27% above its November 2 closing price of $44.89

• The stock recently traded at 89 times the next 12-month earnings vs. a P/E of 203 three months ago

Reuters Recommended Reads

• Nov 2 - Ireland's Ryanair H1 profit falls 15% as fuel costs rise

• Nov 2 - Ireland's Jazz Pharmaceuticals Q3 revenue beats; 2026 outlook lifted

• Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)